Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

Clinical trial NCT05859334 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05859334
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Glioma Recurrent WHO Grade 2 Glioma Recurrent WHO Grade 3 Glioma Recurrent WHO Grade 4 Glioma

Start date: 2024-01-04
Primary completion: 2026-10-23
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.